Longevity & AgingNew Fibromyalgia Treatments Emerge from Psilocybin to Nerve Stimulation
Fibromyalgia affects millions with chronic widespread pain, fatigue, and cognitive fog, yet remains notoriously difficult to treat. This 2026 annual review from the Italian Society of Rheumatology synthesizes the past year's most promising advances. Pharmacologically, low-dose naltrexone shows continued promise in dampening neuroinflammation, while cannabinoids and serotonergic agents including psilocybin are entering early-phase trials. Intravenous lidocaine remains a niche option for refractory cases. Nutraceuticals targeting mitochondrial function are drawing increased interest. On the non-drug side, structured exercise programs, digital rehabilitation platforms, non-invasive brain stimulation, and vagal nerve stimulation are gaining traction. The review reinforces that no single therapy suffices and that a personalized, multimodal biopsychosocial strategy remains the gold standard for managing this complex syndrome.
